Pemvidutide Alcohol Data Set for Liver Meeting

Altimmune will present Phase 2 RECLAIM results for pemvidutide in adults with moderate-to-severe alcohol use disorder at AASLD The Liver Meeting 2026.

Updated on Nov. 5, 2026 in Substance Abuse

Row of unlabeled amber-liquid glass vials in a metal rack on a laboratory bench, with a pipette resting in the foreground under soft daylight. — Altimmune will present late-breaking Phase 2 RECLAIM data on pemvidutide for moderate-to-severe alcohol use disorder at AASLD's Liver Meeting in Denver on November 9. AI Illustration. Upload story photo >

Altimmune will present late-breaking oral data from the RECLAIM Phase 2 trial of pemvidutide in moderate-to-severe alcohol use disorder on Monday, November 9, 2026, at 10:30 a.m. MT in Denver. The trial met its primary endpoint of a statistically significant reduction in heavy drinking days per week versus placebo.

Why it matters

Alcohol use disorder has few approved pharmacotherapies, and the RECLAIM results add data on a glucagon/GLP-1 receptor agonist in this indication. The FDA recognizes the trial's secondary endpoints as registrational, and the company plans to discuss its Phase 3 program at an End-of-Phase 2 meeting in December.

The RECLAIM trial randomized approximately 100 adults with moderate-to-severe alcohol use disorder 1:1 to pemvidutide 2.4 mg or placebo once weekly for 24 weeks, with participants having a BMI above 25 kg/m2. Full efficacy figures beyond the primary endpoint and the outcome of the planned FDA discussion remain to be disclosed.

The players

Altimmune

Altimmune is a Morristown, New Jersey-based biopharmaceutical company traded on Nasdaq under the ticker ALT that is developing pemvidutide.

Henry R. Kranzler, M.D.

Henry R. Kranzler is a professor at the University of Pennsylvania's Perelman School of Medicine who is presenting the RECLAIM results.

AASLD

The American Association for the Study of Liver Diseases is the professional society that hosts The Liver Meeting, a major annual conference on liver disease research.

The details

Pemvidutide is an investigational balanced glucagon/GLP-1 receptor agonist developed by Altimmune. RECLAIM tested the drug against placebo, and the company reports that it met secondary endpoints including reduction in WHO Risk Drinking Levels and zero heavy drinking days.

July 2026: RECLAIM topline results were announced, meeting the primary endpoint.
November 5-9, 2026: AASLD The Liver Meeting is held in Denver, Colorado.
November 9, 2026, 10:30 a.m. MT: RECLAIM late-breaking oral presentation.
December 2026: End-of-Phase 2 meeting with the FDA is scheduled.

Research Context

Late-breaking oral presentations at AASLD's The Liver Meeting are reserved for new, scientifically important findings that missed the regular abstract deadline. Presenting RECLAIM in that venue places pemvidutide's alcohol use disorder data before hepatology researchers as the drug advances toward registrational discussions with the FDA.

For adults with moderate-to-severe alcohol use disorder, pemvidutide remains investigational and is not yet available outside clinical trials. Any eventual treatment would depend on Phase 3 results and FDA review before it could reach patients.

The takeaway

Pemvidutide is one of several investigational candidates being tested for alcohol use disorder, a condition with limited approved drug options. Readers tracking this area should watch the December FDA meeting for signals on the path to Phase 3.

What happens next

Altimmune is scheduled to meet with the FDA in December 2026 for an End-of-Phase 2 meeting to discuss the Phase 3 registrational program for alcohol use disorder.